TODAY'S HEADLINES

AbbVie to profit from new Viekira Pak uses

The expanded use of Viekira Pak comes just in time for AbbVie, which faces increased competition from Zepatier (Merck), which was recently approved by FDA and is priced around 30% lower than Viekira Pak and the other leading hepatitis C medications, Harvoni and Sovaldi (both Gilead Sciences). Read more

Why FDA pulled cholesterol drugs off market

Despite good news about its Viekira Pak expansion, AbbVie recently had to pull two cholesterol-lowering drugs off the market, after FDA withdrew approval of them. Find out why

CONTINUING PHARMACY EDUCATION

The expanding role of direct oral anticoagulants in the management of thromboembolic disease

This month's CE activity is open for pharmacists and pharmacy technicians: "The expanding role of direct oral anticoagulants in the management of thromboembolic disease." Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

7 new facts about drug spending

Spending on specialty medicines has nearly doubled in the past five years, driven primarily by treatments for hepatitis, autoimmune diseases and oncology, which accounted for $19.3 billion in incremental spending, according to a new report. Find out the other important new facts about US drug spending. Read more

April 29, 2016

National Managed Care Pharmacy Survey 2016

Your input is needed! Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, is seeking your opinion on the current state of pharmacy. Take the survey and you could win a $200 Visa gift card. Answer Now.

Related Articles

Top 3 reasons analysts questioning AbbVie's future performance

Injectable cholesterol-lowering drug has positive results after first test